

# Catherijne A J Knibbe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2343530/publications.pdf>

Version: 2024-02-01

152  
papers

5,206  
citations

70961

41  
h-index

106150

65  
g-index

156  
all docs

156  
docs citations

156  
times ranked

4988  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying the Pharmacodynamics of Morphine in the Treatment of Postoperative Pain in Preverbal Children. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 99-109.	1.0	3
2	Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 401-412.	1.6	5
3	Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants. <i>Archives of Disease in Childhood</i> , 2022, 107, 400-406.	1.0	1
4	Antibiotic prophylaxis for acute cholecystectomy: PEANUTS II multicentre randomized non-inferiority clinical trial. <i>British Journal of Surgery</i> , 2022, 109, 267-273.	0.1	9
5	An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 99-113.	1.5	10
6	Prediction of glomerular filtration rate maturation across preterm and term neonates and young infants using inulin as marker. <i>AAPS Journal</i> , 2022, 24, 38.	2.2	6
7	Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1725-1732.	1.3	1
8	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2217-2226.	1.3	4
9	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1167-1175.	1.6	9
10	Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium. <i>Clinical and Translational Science</i> , 2021, 14, 29-35.	1.5	10
11	The bioavailability and maturing clearance of doxapram in preterm infants. <i>Pediatric Research</i> , 2021, 89, 1268-1277.	1.1	7
12	Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations. <i>Pediatric Research</i> , 2021, 90, 1201-1206.	1.1	3
13	Comment on: "Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II". <i>Clinical Pharmacokinetics</i> , 2021, 60, 677-679.	1.6	2
14	Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years. <i>AAPS Journal</i> , 2021, 23, 53.	2.2	12
15	Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. <i>AAPS Journal</i> , 2021, 23, 65.	2.2	6
16	Towards Evidence-Based Weaning: a Mechanism-Based Pharmacometric Model to Characterize Iatrogenic Withdrawal Syndrome in Critically Ill Children. <i>AAPS Journal</i> , 2021, 23, 71.	2.2	3
17	Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1361-1372.	1.6	9
18	Oral drug dosing following bariatric surgery: General concepts and specific dosing advice. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4560-4576.	1.1	23

#	ARTICLE	IF	CITATIONS
19	Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 1-34.	0.3	3
20	Sedation With Midazolam After Cardiac Surgery in Children With and Without Down Syndrome: A Pharmacokinetic-Pharmacodynamic Study. <i>Pediatric Critical Care Medicine</i> , 2021, 22, e259-e269.	0.2	1
21	Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis. <i>Pharmaceutical Research</i> , 2021, 38, 1711-1720.	1.7	0
22	Predicting Unacceptable Pain in Cardiac Surgery Patients Receiving Morphine Maintenance and Rescue Doses: A Model-Based Pharmacokinetic-Pharmacodynamic Analysis. <i>Anesthesia and Analgesia</i> , 2021, 132, 726-734.	1.1	2
23	The association of polypharmacy with functional decline in elderly patients undergoing cardiac surgery. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	7
24	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 303-317.	1.1	37
25	Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 786-795.	2.3	25
26	Rapid Increase in Clearance of Phenobarbital in Neonates on Extracorporeal Membrane Oxygenation: A Pilot Retrospective Population Pharmacokinetic Analysis. <i>Pediatric Critical Care Medicine</i> , 2020, 21, e707-e715.	0.2	7
27	Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3286-3292.	1.3	9
28	Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1231-1236.	1.0	3
29	The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study. <i>AAPS Journal</i> , 2020, 22, 87.	2.2	18
30	Implications for IV posaconazole dosing in the era of obesity. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1006-1013.	1.3	18
31	Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2028-2039.	1.1	17
32	Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> , 2020, 80, 671-695.	4.9	80
33	The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1291-1301.	1.6	10
34	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. <i>Clinical Pharmacokinetics</i> , 2020, 59, 659-669.	1.6	50
35	A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. <i>AAPS Journal</i> , 2019, 21, 81.	2.2	8
36	Doseâ€¦linearity of the pharmacokinetics of an intravenous [ <sup>14</sup> C]midazolam microdose in children. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2332-2340.	1.1	15

#	ARTICLE	IF	CITATIONS
37	Supervised Multidimensional Item Response Theory Modeling of Pediatric Iatrogenic Withdrawal Symptoms. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 904-912.	1.3	4
38	Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. <i>BMC Anesthesiology</i> , 2019, 19, 15.	0.7	6
39	Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 649-656.	2.4	5
40	Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1609-1620.	1.6	27
41	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 112.	1.7	13
42	Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	9
43	Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1300-1308.	1.0	11
44	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1333-1343.	1.6	11
45	Commentary on the <sc>EMA R</sc>eflection <sc>P</sc>aper on the use of extrapolation in the development of medicines for paediatrics. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 659-668.	1.1	28
46	Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method. <i>AAPS Journal</i> , 2019, 21, 38.	2.2	11
47	Children Are Not Small Adults, but Can We Treat Them As Such?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 34-38.	1.3	16
48	Enteral Acetaminophen Bioavailability in Pediatric Intensive Care Patients Determined With an Oral Microtracer and Pharmacokinetic Modeling to Optimize Dosing. <i>Critical Care Medicine</i> , 2019, 47, e975-e983.	0.4	11
49	Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools. <i>AAPS Journal</i> , 2019, 21, 11.	2.2	2
50	Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 847-855.	1.0	10
51	The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models. <i>Clinical Pharmacokinetics</i> , 2019, 58, 131-138.	1.6	8
52	Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 231-255.	0.9	1
53	Rapidly maturing fentanyl clearance in preterm neonates. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2019, 104, F598-F603.	1.4	22
54	Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 175-185.	1.3	19

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 417-428.	1.5	14
56	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 275-285.	1.5	135
57	Kernel-Based Visual Hazard Comparison (kbVHC): a Simulation-Free Diagnostic for Parametric Repeated Time-to-Event Models. <i>AAPS Journal</i> , 2018, 20, 5.	2.2	8
58	Randomized Controlled Trial on the Influence of Intraoperative Remifentanyl versus Fentanyl on Acute and Chronic Pain after Cardiac Surgery. <i>Pain Practice</i> , 2018, 18, 443-451.	0.9	35
59	Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 358-368.	1.1	25
60	Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 601-611.	1.6	25
61	Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. <i>Drugs</i> , 2018, 78, 1887-1901.	4.9	44
62	Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory. <i>Pharmaceutical Research</i> , 2018, 35, 209.	1.7	8
63	Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study. <i>Nutrition and Diabetes</i> , 2018, 8, 47.	1.5	18
64	First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 374-383.	1.3	23
65	Author's Reply to Reith: "Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults". <i>Clinical Pharmacokinetics</i> , 2018, 57, 1357-1358.	1.6	0
66	Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1585-1591.	0.8	14
67	Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials". <i>Clinical Pharmacokinetics</i> , 2018, 57, 1471-1472.	1.6	2
68	Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen". <i>Clinical Pharmacokinetics</i> , 2018, 57, 897-899.	1.6	0
69	Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. <i>Paediatric Drugs</i> , 2018, 20, 365-374.	1.3	22
70	Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. <i>Pharmaceutical Research</i> , 2018, 35, 182.	1.7	24
71	Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1287-1297.	1.1	8
72	Morphine Pharmacodynamics in Mechanically Ventilated Preterm Neonates Undergoing Endotracheal Suctioning. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 239-248.	1.3	11

#	ARTICLE	IF	CITATIONS
73	Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. <i>Metabolomics</i> , 2017, 13, 9.	1.4	64
74	Randomized clinical trial of extended <i>versus</i> single-dose perioperative antibiotic prophylaxis for acute calculous cholecystitis. <i>British Journal of Surgery</i> , 2017, 104, e151-e157.	0.1	36
75	Successful Use of [ <sup>14</sup> C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1185-1195.	1.6	19
76	Why Has Model-Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 646-656.	2.3	169
77	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1966-1975.	1.1	8
78	Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S15-S21.	1.9	92
79	Evidence-based drug treatment for special patient populations through model-based approaches. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S22-S26.	1.9	37
80	Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1577-1587.	1.6	38
81	Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S27-S31.	1.9	37
82	Towards personalized treatment of pain using a quantitative systems pharmacology approach. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S32-S38.	1.9	17
83	What is the dose of intravenous paracetamol for pain relief in neonates?. <i>Archives of Disease in Childhood</i> , 2017, 102, 649-650.	1.0	7
84	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e183-e191.	2.2	154
85	Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	26
86	Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S90-S97.	1.9	26
87	Paracetamol and morphine for infant and neonatal pain; still a long way to go?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 111-126.	1.3	23
88	Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?. <i>Clinical Pharmacokinetics</i> , 2017, 56, 273-285.	1.6	86
89	Perioperative antibiotic prophylaxis in the treatment of acute cholecystitis (PEANUTS II trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 390.	0.7	9
90	Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. <i>JMIR Research Protocols</i> , 2017, 6, e136.	0.5	17

#	ARTICLE	IF	CITATIONS
91	ORGAN FAILURE AND C-REACTIVE PROTEIN BOTH AFFECT MIDAZOLAM CLEARANCE IN CRITICALLY ILL CHILDREN: A POPULATION PK MODEL. Archives of Disease in Childhood, 2016, 101, e1.8-e1.	1.0	0
92	Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1â€œOHâ€œmidazolam in morbidly obese and weight loss surgery patients. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 20-30.	1.3	30
93	Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutrition and Diabetes, 2016, 6, e228-e228.	1.5	42
94	Infants Operated on for Necrotizing Enterocolitis: Towards Evidence-Based Pain Guidelines. Neonatology, 2016, 110, 190-197.	0.9	12
95	Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Review of Clinical Pharmacology, 2016, 9, 1235-1244.	1.3	23
96	Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 58-66.	2.5	81
97	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrobial Agents and Chemotherapy, 2016, 60, 1013-1021.	1.4	53
98	A randomized controlled trial of daily sedation interruption in critically ill children. Intensive Care Medicine, 2016, 42, 233-244.	3.9	64
99	Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen. Clinical Pharmacokinetics, 2016, 55, 833-847.	1.6	76
100	Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clinical Pharmacokinetics, 2016, 55, 507-524.	1.6	52
101	Paracetamol pharmacokinetics and metabolism in young women. BMC Anesthesiology, 2015, 15, 163.	0.7	16
102	Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. British Journal of Clinical Pharmacology, 2015, 80, 294-303.	1.1	8
103	A Follow-up Study on BMI-SDS and Insulin Resistance in Overweight and Obese Children at Risk for Type 2 Diabetes Mellitus. Global Pediatric Health, 2015, 2, 2333794X1456845.	0.3	1
104	Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. British Journal of Clinical Pharmacology, 2015, 80, 1185-1196.	1.1	38
105	Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. Antimicrobial Agents and Chemotherapy, 2015, 59, 6344-6351.	1.4	41
106	Population Pharmacokinetic Modeling of Thymoglobulinâ® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing. Clinical Pharmacokinetics, 2015, 54, 435-446.	1.6	79
107	Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. European Journal of Clinical Pharmacology, 2015, 71, 1075-1082.	0.8	30
108	Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematology,the, 2015, 2, e194-e203.	2.2	228

#	ARTICLE	IF	CITATIONS
109	Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. <i>Archives of Disease in Childhood</i> , 2015, 100, 763-768.	1.0	29
110	Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 25-34.	0.8	17
111	Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2074-2077.	1.3	47
112	The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. <i>Pharmaceutical Research</i> , 2015, 32, 3927-3936.	1.7	58
113	Pediatric pharmacology: current efforts and future goals to improve clinical practice. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1679-1682.	1.5	6
114	Drug Disposition in Obesity: Toward Evidence-Based Dosing. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 149-167.	4.2	99
115	Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2014, 53, 931-941.	1.6	72
116	Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. <i>Archives of Disease in Childhood</i> , 2014, 99, 267-272.	1.0	46
117	Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1330-1338.	1.3	31
118	The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 149-159.	1.1	50
119	Pediatric Microdose Study of [ <sup>14</sup> C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1045-1051.	1.6	29
120	Remifentanyl versus fentanyl during cardiac surgery on the incidence of chronic thoracic pain (REFLECT): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 466.	0.7	5
121	Population-Based Cohort Study of Anti-Infective Medication Use before and after the Onset of Type 1 Diabetes in Children and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4666-4674.	1.4	11
122	A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates. <i>Pharmaceutical Research</i> , 2014, 31, 754-767.	1.7	67
123	Evidence-Based Morphine Dosing for Postoperative Neonates and Infants. <i>Clinical Pharmacokinetics</i> , 2014, 53, 553-563.	1.6	70
124	Population pharmacokinetics of paracetamol across the human age range from (pre)term neonates, infants, children to adults. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 619-629.	1.0	42
125	Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 715-723.	1.3	113
126	Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1371-1388.	2.0	12



#	ARTICLE	IF	CITATIONS
127	Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration. <i>Pharmaceutical Research</i> , 2014, 31, 2643-2654.	1.7	70
128	METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents – study protocol of a randomized controlled study. <i>Trials</i> , 2014, 15, 207.	0.7	14
129	Disease History and Medication Use as Risk Factors for the Clinical Manifestation of Type 1 Diabetes in Children and Young Adults: An Explorative Case Control Study. <i>PLoS ONE</i> , 2014, 9, e87408.	1.1	4
130	A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults. <i>Clinical Pharmacokinetics</i> , 2013, 52, 555-565.	1.6	41
131	Developmental Changes in Morphine Clearance Across the Entire Paediatric Age Range are Best Described by a Bodyweight-Dependent Exponent Model. <i>Clinical Drug Investigation</i> , 2013, 33, 523-534.	1.1	52
132	An Integrated Population Pharmacokinetic Meta-Analysis of Propofol in Morbidly Obese and Nonobese Adults, Adolescents, and Children. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-8.	1.3	16
133	Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates?. <i>Biomarkers in Medicine</i> , 2012, 6, 283-289.	0.6	8
134	From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part I – Extrapolation of a Covariate Model From Morphine to Zidovudine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2012, 1, 1-9.	1.3	34
135	From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II – Sensitivity to Physiological and Physicochemical Properties. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2012, 1, 1-8.	1.3	30
136	Prediction of Morphine Clearance in the Paediatric Population. <i>Clinical Pharmacokinetics</i> , 2012, 51, 695-709.	1.6	17
137	Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance. <i>Clinical Pharmacokinetics</i> , 2012, 51, 105-117.	1.6	99
138	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. <i>Clinical Pharmacokinetics</i> , 2012, 51, 331-345.	1.6	115
139	Impact of Obesity on Drug Metabolism and Elimination in Adults and Children. <i>Clinical Pharmacokinetics</i> , 2012, 51, 277-304.	1.6	288
140	A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span. <i>Pharmaceutical Research</i> , 2012, 29, 1570-1581.	1.7	67
141	Anti-Xa Levels 4h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2012, 22, 791-796.	1.1	14
142	Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children. <i>Clinical Pharmacokinetics</i> , 2011, 50, 51-63.	1.6	51
143	Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 739-750.	1.6	65
144	Advances in paediatric pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1-8.	1.5	39

#	ARTICLE	IF	CITATIONS
145	Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models. <i>Pharmaceutical Research</i> , 2011, 28, 797-811.	1.7	56
146	The role of population PK&PD modelling in paediatric clinical research. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 5-16.	0.8	175
147	Individualized dosing regimens in children based on population PKPD modelling: Are we ready for it?. <i>International Journal of Pharmaceutics</i> , 2011, 415, 9-14.	2.6	46
148	Prediction of Propofol Clearance in Children from an Allometric Model Developed in Rats, Children and Adults versus a 0.75 Fixed-Exponent Allometric Model. <i>Clinical Pharmacokinetics</i> , 2010, 49, 269-275.	1.6	61
149	Tailor-made drug treatment for children. <i>Drug Discovery Today</i> , 2009, 14, 316-320.	3.2	56
150	Treatment of Pulmonary Embolism in an Extremely Obese Patient. <i>Obesity Surgery</i> , 2009, 19, 1186-1189.	1.1	5
151	Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years. <i>Clinical Pharmacokinetics</i> , 2009, 48, 371-385.	1.6	129
152	Propofol Pharmacokinetics and Pharmacodynamics for Depth of Sedation in Nonventilated Infants after Major Craniofacial Surgery. <i>Anesthesiology</i> , 2006, 104, 466-474.	1.3	47